NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
Incyte Corporation
NanOlogy, LLC
University of Texas Southwestern Medical Center
Gilead Sciences
National Cancer Institute (NCI)